Featured 13F manager
Opaleye Management Inc. James Silverman
Boston, MA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $1.1B
- 58 Positions
- 2026 Q2
- +45.5% QoQ
- Top 5 46.8%
James Silverman files Opaleye Management Inc. as a Form 13F. The latest book is 2026 Q2 at $1.1B, up 45.5% QoQ, led by Liquidia, Eton Pharmaceuticals, and Harrow.
Portfolio
top 5 46.8% · top 10 64.8%
- LQDA - Liquidia 17.7%
- ETON - Eton Pharmaceuticals 9.4%
- HROW - Harrow 9.2%
- IRON - Disc Medicine 5.7%
- URGN - Urogen Pharma 4.8%
- APGE - Apogee Therapeutics 4.7%
- MGTX - Meiragtx 4.3%
- SLGL - Sol-Gel Technologies 3.3%
- RZLT - Rezolute 3.0%
- TGTX - Tg Therapeutics 2.7%
- IMMX - Immix Biopharma 2.2%
- CBIO - Crescent Biopharma 2.1%
- Other 30.9%
AUM over time
Book
| Acelyrin | 20.79% | New | 4,158,638 | $20.90 | $87M | +4,158,638 | +$87M |
| HROW - Harrow Health | 17.19% | Hold | 3,775,000 | $19.04 | $72M | — | — |
| OCUL - Ocular Therapeutix | 7.13% | Reduce −5.3% | 5,780,000 | $5.16 | $30M | −325,900 | −$2M |
| TELA - Tela Bio | 3.83% | Reduce −23.8% | 1,580,000 | $10.13 | $16M | −492,813 | −$6M |
| CRNX - Crinetics Pharmaceuticals | 3.64% | Add +7.5% | 845,000 | $18.02 | $15M | +59,206 | +$3M |
| Keros Therapeutics | 3.39% | Add +48.2% | 352,650 | $40.18 | $14M | +114,650 | +$4M |
| BHVN - Biohaven | 3.09% | Hold | 540,000 | $23.92 | $13M | — | — |
| RYTM - Rhythm Pharmaceuticals | 2.90% | Hold | 735,000 | $16.49 | $12M | — | — |
| IDYA - Ideaya Biosciences | 2.33% | Add +21.0% | 415,000 | $23.50 | $10M | +72,000 | +$5M |
| Morphosys AG | 2.16% | Add +1.3% | 1,209,380 | $7.47 | $9M | +15,380 | +$4M |
| PCVX - Vaxcyte | 2.11% | Hold | 177,000 | $49.94 | $9M | — | — |
| ETON - Eton Pharmaceuticals | 1.91% | Add +4.6% | 2,285,000 | $3.49 | $8M | +100,000 | −$438K |
| GERN - Geron | 1.80% | New | 2,350,000 | $3.21 | $8M | +2,350,000 | +$8M |
| Marinus Pharmaceuticals | 1.62% | Reduce −18.3% | 625,000 | $10.86 | $7M | −140,000 | +$2M |
| Kalvista Pharmaceuticals | 1.55% | Reduce −22.0% | 720,000 | $9.00 | $6M | −203,200 | −$776K |
| Protara Therapeutics | 1.54% | Hold | 2,692,594 | $2.39 | $6M | — | — |
| EWTX - Edgewise Therapeutics | 1.51% | Add +8.7% | 815,000 | $7.75 | $6M | +65,000 | +$1M |
| Cymabay Therapeutics | 1.48% | New | 566,700 | $10.95 | $6M | +566,700 | +$6M |
| URGN - Urogen Pharma | 1.41% | Add +12.9% | 570,000 | $10.35 | $6M | +65,000 | +$1M |
| Theravance Biopharma | 1.35% | Reduce −0.5% | 543,500 | $10.35 | $6M | −2,804 | −$302K |
| Theseus Pharmaceuticals | 1.33% | Add +22.4% | 597,500 | $9.33 | $6M | +109,400 | +$1M |
| ACAD - Acadia Pharmaceuticals | 1.24% | New | 217,000 | $23.95 | $5M | +217,000 | +$5M |
| INTC - Intellia Therapeutics | 1.17% | New | 120,000 | $40.78 | $5M | +120,000 | +$5M |
| LQDA - Liquidia | 1.07% | Reduce −0.8% | 570,700 | $7.85 | $4M | −4,500 | +$505K |
| LRMR - Larimar Therapeutics | 1.04% | Reduce −0.8% | 1,390,000 | $3.13 | $4M | −11,000 | −$2M |
| CYTK - Cytokinetics | 1.01% | Reduce −37.3% | 130,000 | $32.62 | $4M | −77,500 | −$3M |
| TRVI - Trevi Therapeutics | 0.97% | Add +103.6% | 1,701,500 | $2.39 | $4M | +865,700 | +$3M |
| Gossamer Bio | 0.97% | New | 3,370,000 | $1.20 | $4M | +3,370,000 | +$4M |
| FDMT - 4D Molecular Therapeutics | 0.96% | Reduce −29.4% | 221,700 | $18.07 | $4M | −92,300 | −$1M |
| Nyxoah S A | 0.85% | Add +672.8% | 445,000 | $8.01 | $4M | +387,415 | +$3M |
| Edap Tms S A | 0.84% | Reduce −0.6% | 380,000 | $9.22 | $4M | −2,400 | −$730K |
| Karyopharm Therapeutics | 0.76% | Reduce −36.5% | 1,785,000 | $1.79 | $3M | −1,025,800 | −$8M |
| IOVA - Iovance Biotherapeutics | 0.71% | Hold | 421,000 | $7.04 | $3M | — | — |
| STXS - Spectrum Pharmaceuticals | 0.71% | Add +254.6% | 3,074,995 | $0.9600 | $3M | +2,207,895 | +$1M |
| CATBUSD - Astria Therapeutics | 0.61% | Add +1.0% | 305,000 | $8.33 | $3M | +3,000 | −$2M |
| CDXS - Codexis | 0.45% | Reduce −10.0% | 675,000 | $2.80 | $2M | −75,000 | −$1M |
| Fortress Biotech | 0.44% | Reduce −27.6% | 3,310,000 | $0.5500 | $2M | −1,263,600 | −$2M |
| Sutro Biopharma | 0.34% | New | 307,000 | $4.65 | $1M | +307,000 | +$1M |
| BDTX - Black Diamond Therapeutics | 0.33% | New | 275,000 | $5.05 | $1M | +275,000 | +$1M |
| Tracon Pharmaceuticals | 0.33% | Hold | 4,764,508 | $0.2910 | $1M | — | — |
| PRQR - Proqr Therapeutics | 0.25% | Hold | 653,000 | $1.62 | $1M | — | — |
| Jasper | 0.22% | Reduce −76.7% | 669,944 | $1.37 | $918K | −2,210,056 | −$4M |
| VSTM - Verastem | 0.18% | New | 102,000 | $7.44 | $759K | +102,000 | +$759K |
| XOMA - XOMA Del | 0.14% | Add +13.2% | 275,000 | $2.16 | $595K | +32,000 | −$5M |
| Igm Biosciiences | 0.14% | New | 63,500 | $9.23 | $586K | +63,500 | +$586K |
| FULC - Fulcrum Therapeutics | 0.11% | New | 143,600 | $3.30 | $474K | +143,600 | +$474K |
| Kezar Life Sciences | 0.06% | Reduce −84.2% | 98,796 | $2.45 | $242K | −526,204 | −$2M |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2023 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| ARQT - Arcutis Biotherapeutics | 1.65% | Exit | 0 | $11.00 | $6M | −502,000 | −$6M |
| PHAT - Phathom Pharmaceuticals | 1.06% | Exit | 0 | $7.14 | $4M | −496,000 | −$4M |
| Relay Therapeutics | 0.62% | Exit | 0 | $16.47 | $2M | −125,500 | −$2M |
| MLYS - Mineralys Therapeutics | 0.54% | Exit | 0 | $15.66 | $2M | −115,000 | −$2M |
| Modular Medical | 0.08% | Exit | 0 | $1.45 | $266K | −183,500 | −$266K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 58 | $1.1B | +45.5% | 13F-HR | 8/14/2026 | 000142050626001803 |
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
23 processed 13Fs on this site · 2021 Q3–2026 Q2